1. Bicêtre hospital experience with sirolimus-based therapy in human renal transplantation: the Sirolimus European Renal Transplant Study.
- Author
-
Charpentier B, Groth CG, Bäckman L, Morales JM, Calne R, Kreis H, Lang P, Touraine JL, Claesson K, Campistol JM, Durand D, Wramner L, and Brattström C
- Subjects
- Adrenal Cortex Hormones therapeutic use, Azathioprine therapeutic use, Cyclosporine therapeutic use, Drug Therapy, Combination, France, Graft Rejection epidemiology, Hospitals, University, Humans, Hypercholesterolemia chemically induced, Hypercholesterolemia epidemiology, Hypertriglyceridemia chemically induced, Hypertriglyceridemia epidemiology, Immunosuppressive Agents adverse effects, Immunosuppressive Agents therapeutic use, Methylprednisolone therapeutic use, Prednisolone therapeutic use, Prednisone therapeutic use, Sirolimus adverse effects, Kidney Transplantation immunology, Sirolimus therapeutic use
- Abstract
In 11 European centers, first cadaveric renal allograft recipients were randomized to CsA (n = 42) or sirolimus (n = 41). Dosing of these agents was concentration-controlled and open-labeled. All patients received corticosteroids and azathioprine. At 12 months, graft survival (98% sirolimus vs 93% CsA), patient survival (100% vs 98%), and incidence of biopsy-confirmed acute rejection (41% vs 38%) were similar. Serum creatinine was lower with sirolimus, significantly (P
- Published
- 2003
- Full Text
- View/download PDF